CERE vs. ASND, LEGN, JAZZ, ITCI, CYTK, ELAN, BPMC, VKTX, ROIV, and IONS
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
Ascendis Pharma A/S has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Cerevel Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Cerevel Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Cerevel Therapeutics has a net margin of 0.00% compared to Cerevel Therapeutics' net margin of -152.68%. Ascendis Pharma A/S's return on equity of -100.14% beat Cerevel Therapeutics' return on equity.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Ascendis Pharma A/S received 254 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 65.65% of users gave Ascendis Pharma A/S an outperform vote.
Ascendis Pharma A/S currently has a consensus target price of $173.88, indicating a potential upside of 29.83%. Cerevel Therapeutics has a consensus target price of $42.67, indicating a potential upside of 1.44%. Given Cerevel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Cerevel Therapeutics.
In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 15 mentions for Ascendis Pharma A/S and 3 mentions for Cerevel Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.61 beat Cerevel Therapeutics' score of 0.25 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
Summary
Cerevel Therapeutics beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cerevel Therapeutics Competitors List
Related Companies and Tools
